Press Releases

Gilead Sciences Announces Changes to Senior Management Team

Gilead Sciences Announces Termination of Its U.S. Development Program for Adefovir Dipivoxil for HIV

Gilead Begins Multinational Phase III Trial of Once Daily Oral Anti-HIV Drug, Tenofovir Disoproxil Fumarate

Roche Announces New Data on Recently Approved Tamiflu™, First Pill to Treat the Most Common Strains of Influenza (A & B)

Gilead Sciences Announces Results of FDA Advisory Panel on Anti-HIV Agent, Adefovir Dipivoxil 60 Mg

Roche Receives FDA Approval Of TAMIFLU™, First Pill To Treat The Most Common Strains Of Influenza (A&B)

Gilead Announces Third Quarter 1999 Financial Results

1999 Third Quarter Highlights

Gilead Sciences Completes European Marketing Authorisation Application For Anti-HIV Agent Adefovir Dipivoxil 60 Mg

Gilead Sciences Amends Stockholder Rights Plan

AmBisome® Phase III Study For Cryptococcal Meningitis

Preliminary Phase II Clinical Results For Once-Daily Anti-HIV Agent, Tenofovir DF, Presented At ICAAC

First Approval of Roche’s Tamiflu™, a New Flu Treatment

Gilead Sciences Announces Acceptance Of Late Breaker Abstract At Upcoming Scientific Conference

Gilead Acquisition Of NeXstar Completed

Gilead Announces Second Quarter 1999 Financial Results

Gilead Sciences and NeXstar Pharmaceuticals Announce Date for Special Stockholders Meetings to Approve Merger

Hoffmann-La Roche Submits New Drug Application to Market New Flu Pill

Gilead Announces First Quarter 1999 Financial Results

Gilead Presents Preliminary Clinical Data Demonstrating Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus

Gilead Begins Multinational Phase III Trial of Hepatitis B Drug, Adefovir Dipivoxil

Gilead Sciences and NeXstar Pharmaceuticals to Merge

Gilead Announces Fourth Quarter and 1998 Year-End Financial Results